RT Journal Article SR Electronic T1 Rapid identification of Sars-CoV-2 variants of concern using the portable peakPCR platform JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.21.21256124 DO 10.1101/2021.05.21.21256124 A1 Hosch, Salome A1 Bechtold, Philippe A1 Wagner, Philipp A1 Ruiz-Serrano, Amalia A1 Gregorini, Michele A1 Siegrist, Denise A1 Engler, Olivier A1 Stark, Wendelin J. A1 Daubenberger, Claudia A. A1 Schindler, Tobias YR 2021 UL http://medrxiv.org/content/early/2021/05/21/2021.05.21.21256124.abstract AB The need for tools which allow rapid detection and continuous monitoring of Sars-CoV-2 variants of concern (VOC) is greater than ever, as these variants are more transmissible and therefore increase the pressure of COVID-19 on healthcare systems. To address this demand, we aimed to develop and evaluate a robust and fast diagnostic approach for identification of Sars-CoV-2 VOC-associated spike gene mutations. Our diagnostic assays detect the E484K and N501Y SNPs as well as a spike gene deletion (HV69/70) and can be run on standard laboratory equipment or on the portable rapid diagnostic technology platform peakPCR. The assays achieved excellent diagnostic performance when tested with RNA extracted from culture-derived Sars-CoV-2 VOC lineages. Simplicity of usage and the relatively low costs are advantages which make our approach well-suited for decentralized and rapid testing, especially in resource limited settings.Competing Interest StatementPB, MG and WJS are co-inventors on a corresponding patent application around the detection platform and shareholders of the ETH spin-off company Diaxxo AG. TS has consulted for Diaxxo AG. All other authors declare no competing interests.Funding StatementFunding for PB and MG was provided by the Botnar Research Centre for Child Health as part of the Fast Track Call for Acute Global Health Challenges as well as the BRIDGE programme by Swiss National Science Foundation and Innosuisse.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no clinical patient samples were usedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.